Growth & profitability
- Revenue has declined 5.9% per year over the past 5 years.
- Operating margin has contracted, at -754.4% in the latest year.
Financial health
- Total debt has grown slower than revenue (-79.4% vs -5.9% per year).
ORMP Financials ORAMED PHARMACEUTICALS INC.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $2M | $64M | 0.7% | -754.4% | -$9M | — | $46M |
| 2024 | — | -$19M | — | — | -$8M | — | $54M |
| 2023 | $1M | $5M | 0.0% | -1176.8% | -$11M | — | $9M |
| 2022 | $3M | -$37M | 0.0% | -1502.0% | -$28M | $25000 | $40M |
| 2021 | $3M | -$23M | 0.0% | -896.2% | -$22M | $13M | $77M |
| 2020 | $3M | -$12M | 0.0% | -433.8% | -$13M | — | $19M |
| 2019 | $3M | -$14M | 96.7% | -541.3% | -$13M | $12M | $3M |
| 2018 | $2M | -$13M | 103.5% | -552.3% | -$15M | $14M | $5M |
| 2017 | $2M | -$10M | 92.4% | -438.6% | -$6M | — | $4M |
| 2016 | $641000 | -$11M | 23.6% | -1561.6% | $5M | — | $4M |
| 2015 | — | -$7M | — | — | -$5M | — | $3M |
| 2014 | — | -$6M | — | — | -$4M | — | $2M |
| 2014 | — | -$24M | — | — | -$17M | — | $3M |
| 2013 | — | -$23M | — | — | -$15M | — | $1M |
| 2013 | — | $4M | — | — | -$3M | — | $2M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | $38M | — | — | -$3M | — | $13M |
| Dec '25 | $0 | $10M | — | — | -$468000 | — | $46M |
| Sep '25 | $0 | $48M | — | — | -$2M | — | $52M |
| Jun '25 | $0 | $13M | — | — | -$4M | — | $16M |
| Mar '25 | $2M | -$8M | 0.7% | -225.0% | -$4M | — | — |
| Dec '24 | — | -$10M | — | — | -$2M | — | $54M |
| Sep '24 | — | -$20M | — | — | -$7M | — | — |
| Jun '24 | — | $9M | — | — | $2M | — | — |
| Mar '24 | — | $2M | — | — | -$1M | — | $19M |
| Dec '23 | $0 | $13M | — | — | -$1M | — | $9M |
| Sep '23 | $0 | -$3M | — | — | -$726000 | $150M | — |
| Jun '23 | $674000 | -$1M | 0.0% | -562.5% | -$3M | — | — |
| Mar '23 | $666000 | -$3M | 0.0% | -782.0% | -$6M | — | — |
| Dec '22 | $681000 | -$9M | 0.0% | -1430.2% | -$8M | $25000 | $40M |
| Sep '22 | $682000 | -$7M | 0.0% | -1200.7% | -$2M | $5M | — |
| Jun '22 | $674000 | -$11M | 0.0% | -1693.9% | -$9M | $7M | — |
| Mar '22 | $666000 | -$11M | 0.0% | -1689.5% | -$9M | $9M | — |
| Dec '21 | $904000 | -$12M | 0.0% | -1363.5% | -$11M | $12M | — |
| Nov '21 | $674000 | -$8M | 0.0% | -1195.8% | — | $12M | $32M |
| Sep '21 | $682000 | — | 0.0% | -1097.5% | — | — | — |
Valuation over time
How the market has priced ORMP against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 24.1× (Jan '24) to 3.2× (Jun '26).
- The price-to-sales ratio has risen from 33.2× (Mar '23) to 102.5× (Jun '26).
P/E
P/S
Frequently asked questions
Is ORMP growing its revenue and profit?
Over the past 5 years, ORAMED PHARMACEUTICALS INC.'s revenue has declined 5.9% per year. These are computed facts, not advice.
How much debt does ORMP have?
As of FY2025, ORAMED PHARMACEUTICALS INC. reported — of total debt against $46M of cash.
What is ORMP's profit margin?
In FY2025, gross margin was 0.7%, operating margin -754.4%, and net margin 3202.5%.
What is ORMP's P/E ratio?
As of Jun '26, ORAMED PHARMACEUTICALS INC. traded at a price-to-earnings ratio of about 3.2× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.